© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 21, 1807-1808,
November 3, 1999
© 1999 Oxford University Press
NEWS |
Awards, Appointments, Announcements
The Association of Community Cancer Centers, Rockville, Md., presented Leslie Ford, M.D., with its Outstanding Achievement Award. Ford is associate director for clinical research in the National Cancer Institute's Division of Cancer Prevention.
|
ACCC honored Ford for "her significant efforts in enhancing clinical research through the NCI's Community Clinical Oncology Program and her leadership in the Breast Cancer Prevention Trial."
MSK Names Varmus
Memorial Sloan-Kettering Cancer Center, New York, named Harold E. Varmus, M.D., as its next president and chief executive officer. Varmus, a Nobel laureate, has been director of the National Institutes of Health since 1993.
|
Ruth Kirschstein, M.D., deputy director of NIH, will serve as acting director after Varmus leaves NIH at the end of 1999.
At Memorial Sloan-Kettering, Varmus succeeds Paul A. Marks, M.D., who has been president and CEO since 1980 and who announced last year his plans to step down.
Douglas A. Warner III, chairman of Memorial Sloan-Kettering's Boards of Overseers and Managers, said that Varmus "combines an extraordinary understanding of the biology of cancer and sensitivity to the clinical needs of cancer patients with the vision to take our great institution into the next century."
Donna Shalala, secretary of the U.S. Department of Health and Human Services, called Varmus's appointment "one of the most important accomplishments" of the Clinton Administration. "History will judge him as the leader who brought new energy, vision, and excitement to the world's greatest scientific institution," she said in a statement.
Duke Names McBride
The Duke University Comprehensive Cancer Center, Durham, N.C., appointed Colleen M. McBride, Ph.D., as director of the center's Cancer Prevention, Detection, and Control Research Program.
McBride is associate professor of community and family medicine at Duke and a behavioral epidemiologist. She has been interim director of the program since 1997.
UM Appoints Todd
The University of Michigan Medical School, Ann Arbor, named Robert F. Todd III, M.D., Ph.D., as the first Frances and Victor Ginsberg Professor of Hematology/Oncology.
Todd has been chief of the university's Division of Hematology/Oncology in the Department of Medicine since 1993, and recently became associate vice president for research (health affairs).
Straus Heads NCCAM
The new director of the National Institutes of Health's National Center for Complementary and Alternative Medicine is Stephen E. Straus, M.D. Straus has been, since 1991, chief of the Laboratory of Clinical Investigation at the National Institute of Allergy and Infectious Diseases.
Harold E. Varmus, M.D., NIH director, said that Straus's appointment, "with his experience in alternative therapies and his expertise in clinical evidence, will result in significant expansion of clinical research in this field. He brings to this position a clear sense of leadership, strong management and organizational expertise, and superb communication skills."
Berry Moves to Anderson
The University of Texas M. D. Anderson Cancer Center, Houston, named Donald Berry, Ph.D., as chairman of its new Department of Biostatistics. He will hold the Frank T. McGraw Memorial Chair for Cancer Research.
Berry had been at Duke University, Durham, N.C., and is the faculty statistician on the Breast Cancer Committee of Cancer and Leukemia Group B, a national cooperative group conducting clinical trials. He also is a statistical editor of this Journal.
Faculty Appointment
The Roswell Park Cancer Institute, Buffalo, N.Y., appointed Gerold Bepler, M.D., Ph.D., and Nithya Ramnath, M.D., to the faculty of the Lung Section in the Department of Medicine.
|
|
Bepler, who leaves Duke University, Durham, N.C., will be associate professor of medicine and director of the Lung Section. Ramnath, who had been at Medina Community Hospital, Hondo, Texas, will be assistant professor of medicine.
Lawrence Leichman, M.D., chairman of RPCI's Department of Medicine, said the two additions to the faculty "will enhance the delivery of care to lung cancer patients in western New York and beyond."
Clarification
In the news article, "KS Enters Y2K Still Riddled With Many Questions," (News, Oct. 6, 1999) Robert Yarchoan, M.D., was quoted as saying that "in people with aggressive KS, substances like IL-12 may not be effective due to its toxic side effects." Yarchoan provided the following clarification of this statement: "Treatment of KS in its earliest stages may be most effective because patients with very aggressive KS may require a more rapidly acting therapy. Additional studies will be needed to clarify this issue." It should be noted that current IL-12 therapy for KS is conservative and shows little toxicity and has activity.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||